JP MORGAN/PUT/VERTEX PHARMACEUTICALS/260/0.1/17.01.25 | Market Closed - Börse Stuttgart 07:48:52 31/05/2024 BST | ||
| 0.17 EUR | -10.53% |
|
| 1 month | -55.26% | ||
| 3 months | -48.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.17 | -10.53% |
| 30/05/24 | 0.19 | +18.75% |
| 29/05/24 | 0.16 | +23.08% |
| 28/05/24 | 0.13 | -7.14% |
| 27/05/24 | 0.14 | -12.50% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 07:48 am
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL07TZ |
| ISIN | DE000JL07TZ5 |
| Date issued | 12/04/2023 |
| Strike | 260 $ |
| Maturity | 17/01/2025 (229 Days) |
| Parity | 10 : 1 |
| Emission price | 2.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.65 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.5 € |
| Spread % | 78.13% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Warrants
- Warrant
